Position in JSPR
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,236,466
-$2,032,814 QoQ
Shares Held
1,411,492
-21.0% QoQ
Ownership
5.04%
of shares outstanding
% of Portfolio
0.35%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JSPR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026ACORN CAPITAL ADVISORS, LLC holds $350,733,296 across 21 Biotechnology names. JSPR ranks #19 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TERN |
Terns Pharmaceuticals, Inc.
|
1,746,264 | $92,063,038 | |
| 2 | CGON |
CG Oncology, Inc.
|
1,130,501 | $76,512,307 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
1,673,420 | $30,088,091 | |
| 4 | PBYI |
Puma Biotechnology, Inc.
|
4,131,299 | $26,399,000 | |
| 5 | TRVI |
Trevi Therapeutics, Inc.
|
2,144,844 | $25,587,988 | |
| 6 | CADL |
Candel Therapeutics, Inc.
|
3,497,948 | $17,139,945 | |
| 7 | BCAX |
Bicara Therapeutics Inc.
|
643,382 | $12,796,867 | |
| 8 | OKUR |
OnKure Therapeutics, Inc.
|
2,839,674 | $11,756,250 |
All Filings in JSPR
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,236,466 | 1,411,492 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $3,269,280 | 1,786,492 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,290,683 | 1,382,640 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||